View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
February 26, 1997updated 05 Sep 2016 12:40pm

DRUG DESIGN: CAMBRIDGE STAKE GOES TO OXFORD

By CBR Staff Writer

Computer-aided drug design specialist Oxford Molecular Group Plc has made an initial cash investment of 500,000 pounds in drug research firm Cambridge Combinatorial Ltd, giving it a 20% stake. Cambridge will offer three further tranches of deferred shares, equivalent to 500,000 pounds to Oxford. The investment has been made as a strategic move to provide a range of integrated drug design services to its pharmaceutical services.

Topics in this article :
Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU